Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Medication: Clinical trials

Expert opinion editorial

The CAROLINA trial: Make or break for sulfonylureas?

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas. 

Get more on: Sulfonylureas | DPP-4 inhibitors | Other diabetes medications

Journal article

A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: Metabolic effects and markers associated with bodyweight loss

This post hoc analysis investigated the metabolic effects and baseline associations with bodyweight loss on coadministration of dapagliflozin and exenatide once weekly among adults with obesity and without diabetes [read more].
Pereira MJ et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0449-6

Get more on:  Medication | Obesity | Type 2 diabetes

Journal article

Long-term effect of the color record method in self-monitoring of blood glucose on metabolic parameters in type 2 diabetes: A 2-year follow-up of the Color IMPACT study

This article evaluates the potential long-term effect of two different color indication methods for self-monitoring of blood glucose on metabolic parameters in insulin-treated type 2 diabetes [read more].
Nishimura A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0457-6

Get more on:  Devices and technology | Type 2 diabetes

Expert opinion editorial

Does setting treatment targets risk the overtreatment of type 2 diabetes in older patients?

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment [read more].

Get more on: Medication | Older adults |  Type 2 diabetes

Expert opinion editorial

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes [read more].

Get more on:  SGLT2 inhibitors | Cardiovascular disease | Expert opinion

Expert opinion editorial

Metformin: What is new with this old medication?

With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded [read more].

Get more on: Type 2 diabetes | Metformin | Medications | Expert opinion

View all highlights

medwireNews

05-10-2018 | Linagliptin | EASD 2018 | News

Favorable long-term cardiovascular safety profile of linagliptin in type 2 diabetes

Findings from the CARMELINA trial suggest that the dipeptidyl peptidase-4 inhibitor linagliptin has a similar cardiovascular safety profile to placebo when added to standard care in high-risk type 2 diabetes patients.

05-10-2018 | Lorcaserin | EASD 2018 | News

Weight loss with lorcaserin linked to improved glycemic profile

Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.

06-11-2017 | Prediabetes | News

Lifestyle interventions have most staying power for diabetes prevention

A meta-analysis shows that although medications and lifestyle changes can both reduce the risk for type 2 diabetes in high-risk patients, only lifestyle modifications have a sustained effect.

View all related news

Journal articles and book chapters

06-11-2018 | Nephropathy | Article

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): A randomized, placebo-controlled, phase 2 trial

de Zeeuw D et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30289-4

03-11-2018 | Liraglutide (T2DM) | Article

Liraglutide and glycemic outcomes in the LEADER trial

Zinman B et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0524-z

21-10-2018 | Sitagliptin | Article

A randomized clinical trial to evaluate the single‐dose pharmacokinetics, pharmacodynamics and safety of sitagliptin in pediatric patients with type 2 diabetes

Fraser IP et al. Pediatr Diabetes 2018. doi: 10.1111/pedi.12790

29-08-2018 | Hypoglycemia | Article

A post hoc pooled analysis to evaluate hypoglycemia risk with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in people with type 2 diabetes on a basal‐only insulin regimen

Bolli GB et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13515

21-08-2018 | Dulaglutide | Article

Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulfonylurea: A 52‐week open‐label, randomized phase 3 trial

Wang W et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13506

15-08-2018 | Insulin glargine | Article

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase 3 INSTRIDE 2 study

Blevins TC et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13495

View all journal articles and book chapters

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

View all

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

View all
Image Credits